- Home
- SANG vs CBIO Comparison
SANG vs CBIO Comparison
Compare SANG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- CBIO
- Stock Information
- Founded
- SANG 1984
- CBIO 2003
- Country
- SANG Canada
- CBIO United States
- Employees
- SANG N/A
- CBIO N/A
- Industry
- SANG Computer Software: Programming Data Processing
- CBIO
- Sector
- SANG Technology
- CBIO
- Exchange
- SANG Nasdaq
- CBIO Nasdaq
- Market Cap
- SANG 194.3M
- CBIO 173.5M
- IPO Year
- SANG 2021
- CBIO N/A
- Fundamental
- Price
- SANG $5.92
- CBIO $12.22
- Analyst Decision
- SANG
- CBIO Strong Buy
- Analyst Count
- SANG 0
- CBIO 5
- Target Price
- SANG N/A
- CBIO $25.60
- AVG Volume (30 Days)
- SANG 2.2K
- CBIO 107.5K
- Earning Date
- SANG 11-05-2025
- CBIO 07-31-2025
- Dividend Yield
- SANG N/A
- CBIO N/A
- EPS Growth
- SANG N/A
- CBIO N/A
- EPS
- SANG N/A
- CBIO N/A
- Revenue
- SANG $238,264,000.00
- CBIO N/A
- Revenue This Year
- SANG N/A
- CBIO N/A
- Revenue Next Year
- SANG $2.38
- CBIO N/A
- P/E Ratio
- SANG N/A
- CBIO N/A
- Revenue Growth
- SANG N/A
- CBIO N/A
- 52 Week Low
- SANG $4.08
- CBIO $10.83
- 52 Week High
- SANG $7.99
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SANG 55.67
- CBIO 39.28
- Support Level
- SANG $5.42
- CBIO $12.09
- Resistance Level
- SANG $5.74
- CBIO $14.50
- Average True Range (ATR)
- SANG 0.16
- CBIO 0.93
- MACD
- SANG -0.00
- CBIO -0.19
- Stochastic Oscillator
- SANG 59.52
- CBIO 3.45
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.